Home Cart 0 Sign in  
X

[ CAS No. 287192-97-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 287192-97-6
Chemical Structure| 287192-97-6
Chemical Structure| 287192-97-6
Structure of 287192-97-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 287192-97-6 ]

Related Doc. of [ 287192-97-6 ]

Alternatived Products of [ 287192-97-6 ]

Product Details of [ 287192-97-6 ]

CAS No. :287192-97-6 MDL No. :MFCD09038026
Formula : C12H19NO2 Boiling Point : -
Linear Structure Formula :- InChI Key :INUWDZDWSJJFSQ-UHFFFAOYSA-N
M.W : 209.29 Pubchem ID :15550481
Synonyms :

Calculated chemistry of [ 287192-97-6 ]

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.75
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 64.37
TPSA : 29.54 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.18 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.04
Log Po/w (XLOGP3) : 1.97
Log Po/w (WLOGP) : 1.97
Log Po/w (MLOGP) : 2.18
Log Po/w (SILICOS-IT) : 1.73
Consensus Log Po/w : 2.18

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.18
Solubility : 1.38 mg/ml ; 0.0066 mol/l
Class : Soluble
Log S (Ali) : -2.22
Solubility : 1.27 mg/ml ; 0.00608 mol/l
Class : Soluble
Log S (SILICOS-IT) : -1.36
Solubility : 9.07 mg/ml ; 0.0434 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.38

Safety of [ 287192-97-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 287192-97-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 287192-97-6 ]
  • Downstream synthetic route of [ 287192-97-6 ]

[ 287192-97-6 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 90965-06-3 ]
  • [ 137076-22-3 ]
  • [ 287192-97-6 ]
YieldReaction ConditionsOperation in experiment
88% With potassium carbonate In methanol at 20℃; At 0 C, to a stirred mixture of 4-formyl-piperidine-1-carboxylic acid tert-butyl ester (358 mg, 1.68 mmols) and potassium carbonate (464 rng, 3.36 mmols) in methanol (16 ml) was added dropwise a solution of (1-diazo-2-oxo-propyl)- phosphonic acid dimethyl ester (323 mg, 1.68 mmols) in methanol (2 ml). The resulting mixture was stirred at room temperature overnight, filtered and concentrated. The residue was chromatographed on silica gel using a solution of ethyl acetate in hexanes (1:5) to provide the title compound (308 mg, 88percent) as colorless crystals. LCMS m/e (154, M - M3u + 2H). (J. Am. Chem. Soc. 2003, 125, 3714.)
88% With potassium carbonate In methanol at 20℃; At 0 C, to a stirred mixture of 4-formyl-piperidine-1-carboxylic acid fert-butyl ester (358 mg, 1.68 mmols) and potassium carbonate (464 mg, 3.36 mmols) in methanol (16 ml) was added dropwise a solution of (1-diazo-2-oxo-propyl)- phosphonic acid dimethyl ester (323 mg, 1.68 mmols) in methanol (2 ml). The resulting mixture was stirred at room temperature overnight, filtered and concentrated. The residue was chromatographed on silica gel using a solution of ethyl acetate in hexanes (1 :5) to provide the title compound (308 mg, 88percent) as colorless crystals. LCMS m/e (154, M - f-Bu + 2H). (J. Am. Chem. Soc. 2003, 725, 3714.)
81% With potassium carbonate In methanol at 20℃; for 18 h; A solution of compound 7 (0.1 g, 0.41 mmol) in methanolwas stirred at room temperature for 10 min. Then compound8 (95 mg, 0.49 mmol) and K2CO3 (113 mg, 0.82 mmol) were added and stirred at room temperature for 18 h. Thereaction mixture was filtered through a celite pad to removeK2CO3. The solvent was evaporated under vacuum. Thenwater was added and the product was extracted by ethylacetate (3 × 30 ml). The crude material was purified bycolumn chromatography to obtain product. Compound 9 Yield 81percent, white solid powder; MS: [M+H]+ 210.09; 1H-NMR (400MHz, CDCl3-D) δ 3.72 (m, 2H),3.20 (m, 2H), 2.06 (s, 1H), 2.12 (d, J = 2.4 Hz, 1H), 1.81(m, 2H), 1.60 (m, 2H), 1.47 (s, 9H). 13C-NMR (100MHz,CDCl3-D) δ 154.8, 86.4, 79.5, 69.5, 31.2, 28.4, 26.7.
55% With potassium carbonate In methanol for 20 h; Example 124; Preparation of tert-butyl 4-(2-(7-(4-(1-(carbamoyl)cyclopropanecarboxamido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)ethynyl)piperidine-1-carboxylate; Step A: Preparation of tert-butyl 4-ethynylpiperidine-1-carboxylate; To a stirred suspension of tert-butyl 4-formylpiperidine-1-carboxylate (0.427 g, 2.00 mmol), K2CO3 (0.553 g, 4.00 mmol), and MeOH (25 mL) was added all at once the Bestman-Ohira reagent, dimethyl 2-oxo-1-diazo-propylphosphonate (0.461 g, 2.40 mmol, see Synthesis 2004, 1, 59-62). Stirring was continued for 20 hours under nitrogen. The reaction was diluted with Et2O (50 mL), washed with a 2:1 mixture of water and aqueous saturated NaHCO3 (20 mL), dried (Na2SO4), filtered, and concentrated in vacuo. Yield: 253 mg (55percent). 1H NMR (400 MHz, CDCl3) δ 3.72 (m, 2H), 3.19 (m, 2H), 2.58 (m, 1H), 2.10 (d, J=2 Hz, 1H), 1.77 (m, 2H), 1.61 (m, 2H), 1.46 (s, 9H).

Reference: [1] Journal of the American Chemical Society, 2003, vol. 125, # 13, p. 3714 - 3715
[2] Patent: WO2007/97937, 2007, A1, . Location in patent: Page/Page column 191
[3] Patent: WO2008/156739, 2008, A1, . Location in patent: Page/Page column 222
[4] Tetrahedron Letters, 2006, vol. 47, # 11, p. 1729 - 1731
[5] Medicinal Chemistry Research, 2018, vol. 27, # 11-12, p. 2437 - 2445
[6] Patent: US2007/197537, 2007, A1, . Location in patent: Page/Page column 101
[7] Journal of Medicinal Chemistry, 2004, vol. 47, # 12, p. 3111 - 3130
[8] Patent: US2014/275153, 2014, A1, . Location in patent: Paragraph 0541
[9] Patent: US2015/218165, 2015, A1, . Location in patent: Paragraph 1175
[10] MedChemComm, 2016, vol. 7, # 9, p. 1797 - 1801
[11] Patent: WO2017/194734, 2017, A1, . Location in patent: Page/Page column 44
  • 2
  • [ 96854-79-4 ]
  • [ 137076-22-3 ]
  • [ 287192-97-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2012, vol. 55, # 1, p. 68 - 83
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 287192-97-6 ]

Alkynes

Chemical Structure| 664362-16-7

[ 664362-16-7 ]

1-Boc-3-Ethynylpiperidine

Similarity: 0.96

Chemical Structure| 403802-41-5

[ 403802-41-5 ]

tert-Butyl 4-(3-hydroxyprop-1-yn-1-yl)piperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 287193-00-4

[ 287193-00-4 ]

1-Boc-3-Ethynylpyrrolidine

Similarity: 0.91

Chemical Structure| 255864-58-5

[ 255864-58-5 ]

tert-Butyl 2-ethynylpiperidine-1-carboxylate

Similarity: 0.89

Chemical Structure| 316141-37-4

[ 316141-37-4 ]

1-Boc-2-Ethynylpyrrolidine

Similarity: 0.85

Amides

Chemical Structure| 664362-16-7

[ 664362-16-7 ]

1-Boc-3-Ethynylpiperidine

Similarity: 0.96

Chemical Structure| 403802-41-5

[ 403802-41-5 ]

tert-Butyl 4-(3-hydroxyprop-1-yn-1-yl)piperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 287193-00-4

[ 287193-00-4 ]

1-Boc-3-Ethynylpyrrolidine

Similarity: 0.91

Chemical Structure| 236406-21-6

[ 236406-21-6 ]

1-Boc-4-(Hydroxymethyl)-4-methylpiperidine

Similarity: 0.90

Chemical Structure| 123855-51-6

[ 123855-51-6 ]

tert-Butyl 4-(hydroxymethyl)piperidine-1-carboxylate

Similarity: 0.90

Related Parent Nucleus of
[ 287192-97-6 ]

Aliphatic Heterocycles

Chemical Structure| 664362-16-7

[ 664362-16-7 ]

1-Boc-3-Ethynylpiperidine

Similarity: 0.96

Chemical Structure| 403802-41-5

[ 403802-41-5 ]

tert-Butyl 4-(3-hydroxyprop-1-yn-1-yl)piperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 287193-00-4

[ 287193-00-4 ]

1-Boc-3-Ethynylpyrrolidine

Similarity: 0.91

Chemical Structure| 236406-21-6

[ 236406-21-6 ]

1-Boc-4-(Hydroxymethyl)-4-methylpiperidine

Similarity: 0.90

Chemical Structure| 123855-51-6

[ 123855-51-6 ]

tert-Butyl 4-(hydroxymethyl)piperidine-1-carboxylate

Similarity: 0.90

Piperidines

Chemical Structure| 664362-16-7

[ 664362-16-7 ]

1-Boc-3-Ethynylpiperidine

Similarity: 0.96

Chemical Structure| 403802-41-5

[ 403802-41-5 ]

tert-Butyl 4-(3-hydroxyprop-1-yn-1-yl)piperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 236406-21-6

[ 236406-21-6 ]

1-Boc-4-(Hydroxymethyl)-4-methylpiperidine

Similarity: 0.90

Chemical Structure| 123855-51-6

[ 123855-51-6 ]

tert-Butyl 4-(hydroxymethyl)piperidine-1-carboxylate

Similarity: 0.90

Chemical Structure| 146093-46-1

[ 146093-46-1 ]

4-(Aminoethyl)-1-N-Boc-piperidine

Similarity: 0.90